Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 15/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 13/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284468 | 0.89 | SLC5A2 (0.43) | SLC5A2SLC5A1NPC1RAB9APTPN1 | |
| SCHEMBL4294434 | 0.88 | SLC5A2 (0.41) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL4285310 | 0.85 | SLC5A2 (0.49) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL4290264 | 0.81 | SLC5A2 (0.40) | SLC5A2SLC5A1NPC1RAB9APTPN1 | |
| SCHEMBL4284267 | 0.80 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL4284485 | 0.80 | SLC5A2 (0.46) | SLC5A2SLC5A1 | |
| SCHEMBL4292210 | 0.80 | SLC5A2 (0.36) | SLC5A2SLC5A1 | |
| SCHEMBL4285652 | 0.80 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| SCHEMBL4289187 | 0.80 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| SCHEMBL4288361 | 0.80 | HTR2A (0.34) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885NPC1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.